HORMONE REPLACEMENT THERAPY WITH CLIMEN© AND ITS EFFECTS ON THE BREAST TISSUE
作者： Svetlana Antevska Grujoska , Vesna Livrinova , Vesna Antovska , Gordana Kiproska , Goran Dimitrov
DOI:
关键词:
摘要: Objective. To evaluate the effect of hormone replacement therapy on breast changes in postmenopausal women. Material and methods. The study includes 35 women with natural or surgical menopause who were treated sequential estrogen/progestogen (E/P HRT) during one year. therapeutic program consisted three weeks treatment estradiol valerate 2 mg/day orally, combined ciproterone acetate 1 last 10 days (Climen – Schering) followed by week pause. Before start E/P HRT basic mammography ultrasound examination tissue was performed all patients. At end after 12 cycles, control ultrasonographic done. Results. In short-term 18 patients (51.43%) showed regression finding, 15 (42.86%) stagnation, only (5.71%) progression finding (D=0.27, p<0.01). Conclusion. A clear consensus regarding relationship between cancer risk cannot yet be drawn. Stru~ni ~lanak
参考文章(18)
A Fanucchi, Andrea Genazzani, S Cosio, Angiolo Gadducci, Hormone replacement therapy and gynecological cancer. Anticancer Research. ,vol. 17, pp. 3793- 3798 ,(1997)
M D Cahn, T Tran, C P Theur, J A Butler, Hormone replacement therapy and the risk of breast lesions that predispose to cancer. American Surgeon. ,vol. 63, pp. 858- 860 ,(1997)
Nachtigall Mj, Nachtigall Rd, Nachtigall Rh, Nachtigall Le, Smilen Sw, Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstetrics & Gynecology. ,vol. 80, pp. 827- 830 ,(1992)
Lauritzen C, Cancer risk under hormone therapy Therapeutische Umschau. Revue thérapeutique. ,vol. 51, pp. 755- ,(1994)
David Moher, Kenneth F Schulz, Douglas G Altman, The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials BMC Medical Research Methodology. ,vol. 1, pp. 2- 2 ,(2001) , 10.1186/1471-2288-1-2
A Gayet, J Estève, B Séradour, L Piana, J Jacquemier, Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign. European Journal of Cancer. ,vol. 39, pp. 1738- 1745 ,(2003) , 10.1016/S0959-8049(02)00837-7
Hermann P.G Schneider, HRT and cancer risks. Maturitas. ,vol. 43, pp. 35- 52 ,(2002) , 10.1016/S0378-5122(02)00147-0
Christopher I Li, Kathleen E Malone, Peggy L Porter, Noel S Weiss, Mei-Tzu C Tang, Kara L Cushing-Haugen, Janet R Daling, Relationship between long durations and different regimens of hormone therapy and risk of breast cancer JAMA. ,vol. 289, pp. 3254- 3263 ,(2003) , 10.1001/JAMA.289.24.3254
Janet L. Stanford, Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-aged Women JAMA. ,vol. 274, pp. 137- 142 ,(1995) , 10.1001/JAMA.1995.03530020055032
John Eden, Progestins and breast cancer. American Journal of Obstetrics and Gynecology. ,vol. 188, pp. 1123- 1131 ,(2003) , 10.1067/MOB.2003.201